1. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
- Author
-
Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, and Sheng LJ
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Adenocarcinoma genetics, Adult, Aged, Carcinoma, Squamous Cell genetics, Docetaxel, Female, Gene Frequency, Genotype, Haplotypes, Humans, Lung Neoplasms genetics, Male, Middle Aged, Polymorphism, Single Nucleotide, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Cisplatin therapeutic use, Lung Neoplasms drug therapy, Taxoids therapeutic use
- Abstract
Background: The multidrug resistance gene 1 (MDR1) encodes P-glycoprotein (P-gp), which plays an important role in mediating multidrug resistance to chemotherapeutic agents. MDR1 gene polymorphisms may have an impact on the expression and function of P-gp, thereby influencing the response to chemotherapy., Objectives: To investigate whether the MDR1 2677 and 3435 genotypes are associated with the sensitivity of non-small-cell lung cancer (NSCLC) to docetaxel., Methods: In this study we investigated the potential association of MDR1 2677G>T at exon 21, 3435C>T at exon 26 and their haplotypes with chemotherapy response of 54 Han Chinese patients with NSCLC. The patients were treated with docetaxel-cisplatin., Results: The 2677 GG genotype was associated with a significantly better response to chemotherapy compared with the combined 2677 GT and TT genotype (p = 0.035). The 3435 CC genotype was also associated with a better response to chemotherapy compared with the combined 3435 CT and TT genotypes although the difference was not statistically significant (p = 0.123). Moreover, patients harboring the 2677G-3435C haplotype had a statistically significant better response to chemotherapy compared with those with the other haplotypes combined (p = 0.015)., Conclusion: Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLC patients., (Copyright 2008 S. Karger AG, Basel.)
- Published
- 2009
- Full Text
- View/download PDF